Company Overview - BioMarin Pharmaceutical (BMRN) is expected to report a year-over-year increase in earnings, with a projected quarterly earnings per share (EPS) of $0.56, reflecting a change of +3.7% [3] - Revenues are anticipated to reach $659.73 million, representing a 10.8% increase from the same quarter last year [4] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [5] - The Most Accurate Estimate for BioMarin is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.67%, suggesting a bearish outlook from analysts [11] Historical Performance - In the last reported quarter, BioMarin exceeded expectations by posting earnings of $0.71 per share against an expected $0.60, achieving a surprise of +18.33% [14] - Over the past four quarters, the company has beaten consensus EPS estimates three times [15] Industry Comparison - Bristol Myers Squibb (BMY), another player in the biomedical industry, is expected to report an EPS of $1.64 for the same quarter, indicating a year-over-year decline of -6.3% [19] - Bristol Myers' revenues are projected to be $11.5 billion, up 2.5% from the previous year [19] - The consensus EPS estimate for Bristol Myers has been revised 1% lower in the last 30 days, resulting in an Earnings ESP of -0.15% [20]

Investors in BioMarin Pharmaceutical (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sept 20, 2024 $40.00 Call had some of the highest implied volatility of all equity options today. What do the Analysts Think? Given the way analysts feel about BioMarin Pharmaceutical right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium ...

SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through ...

As we near the end of the ongoing reporting cycle in the biotech sector, the picture is pretty ho-hum. The bigwigs in the sector have already reported and the results have been mostly mixed. Nonetheless, the outlook provided by most of these companies is encouraging, indicating bright prospects driven by new drug approvals and positive pipeline updates. The macroeconomic environment, however, remains uncertain and growth might be sluggish.Nonetheless, companies in this volatile biotech industry continue to ...

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions BioMarin-Sponsored Phase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence SAN RAFAEL, Calif., May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in ch ...

| --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

BioMarin Pharmaceutical Inc. (BMRN) reported first-quarter 2024 adjusted earnings per share of 71 cents, beating the Zacks Consensus Estimate of 60 cents. The reported earnings rose 18.3% year over year, as higher sales were partially offset by rising R&D expenses.Total revenues were $648.8 million in the reported quarter, up 9% year over year on a reported basis and 13% on a constant currency basis. Strong sales of Voxzogo drove revenues. The top line, however, missed the Zacks Consensus Estimate of $649.8 ...

BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q1 2024 Earnings Conference Call April 24, 2024 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President & CEO Henry Fuchs - President, Worldwide Research & Development Brian Mueller - EVP & CFO Jeffrey Ajer - EVP & Chief Commercial Officer Conference Call Participants Phil Nadeau - TD Cowen Geoff Meacham - Bank of America Salveen Richter - Goldman Sachs Christopher Raymond - Piper Sandler Akash Tewari - Jefferies Jessica Fye - JPMorg ...

B!OMARIN BiOMARIN Forward-Looking Statements 4 This presentation includes both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income excluding amortization of intangible assets, stock-based compensation expense, and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Operating Margin percentage is defined by the c ...

For the quarter ended March 2024, BioMarin Pharmaceutical (BMRN) reported revenue of $648.83 million, up 8.8% over the same period last year. EPS came in at $0.71, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $649.75 million. With the consensus EPS estimate being $0.60, the EPS surprise was +18.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...